Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505286-84-00

Acronym

CSET N° 2017/2523

Enrollment

140

Registered

2024-03-27

Start date

2018-06-25

Completion date

Unknown

Last updated

2024-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic well differentiated neuroendocrine tumors (NET)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026